111 related articles for article (PubMed ID: 16647240)
1. Naltrexone renders one-session exposure therapy less effective: a controlled pilot study.
Kozak AT; Spates CR; McChargue DE; Bailey KC; Schneider KL; Liepman MR
J Anxiety Disord; 2007; 21(1):142-52. PubMed ID: 16647240
[TBL] [Abstract][Full Text] [Related]
2. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Ressler KJ; Rothbaum BO; Tannenbaum L; Anderson P; Graap K; Zimand E; Hodges L; Davis M
Arch Gen Psychiatry; 2004 Nov; 61(11):1136-44. PubMed ID: 15520361
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
Hofmann SG; Meuret AE; Smits JA; Simon NM; Pollack MH; Eisenmenger K; Shiekh M; Otto MW
Arch Gen Psychiatry; 2006 Mar; 63(3):298-304. PubMed ID: 16520435
[TBL] [Abstract][Full Text] [Related]
4. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation.
Powers MB; Smits JA; Otto MW; Sanders C; Emmelkamp PM
J Anxiety Disord; 2009 Apr; 23(3):350-6. PubMed ID: 19223151
[TBL] [Abstract][Full Text] [Related]
5. Naltrexone for heroin dependence treatment in St. Petersburg, Russia.
Krupitsky EM; Zvartau EE; Masalov DV; Tsoi MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
J Subst Abuse Treat; 2004 Jun; 26(4):285-94. PubMed ID: 15182893
[TBL] [Abstract][Full Text] [Related]
6. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
7. A randomized control trial of group counseling in a naltrexone treatment program.
Tucker T; Ritter A; Maher C; Jackson H
J Subst Abuse Treat; 2004 Dec; 27(4):277-88. PubMed ID: 15610829
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial.
Roth AS; Ostroff RB; Hoffman RE
J Clin Psychiatry; 1996 Jun; 57(6):233-7. PubMed ID: 8666558
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
Grant JE; Kim SW; Odlaug BL
Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R
Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042
[TBL] [Abstract][Full Text] [Related]
11. Opioid antagonists in the treatment of impulse-control disorders.
Kim SW
J Clin Psychiatry; 1998 Apr; 59(4):159-64. PubMed ID: 9590665
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
[TBL] [Abstract][Full Text] [Related]
13. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users.
Hulse GK; Tait RJ
Addict Biol; 2003 Sep; 8(3):337-42. PubMed ID: 13129836
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear.
Guastella AJ; Dadds MR; Lovibond PF; Mitchell P; Richardson R
J Psychiatr Res; 2007 Sep; 41(6):466-71. PubMed ID: 16828803
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences.
King A; de Wit H; Riley RC; Cao D; Niaura R; Hatsukami D
Nicotine Tob Res; 2006 Oct; 8(5):671-82. PubMed ID: 17008194
[TBL] [Abstract][Full Text] [Related]
16. Cognitive-behavioral treatment for specific phobias with a child demonstrating severe problem behavior and developmental delays.
Davis TE; Kurtz PF; Gardner AW; Carman NB
Res Dev Disabil; 2007; 28(6):546-58. PubMed ID: 16950598
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.
Johansson BA; Berglund M; Lindgren A
Addiction; 2006 Apr; 101(4):491-503. PubMed ID: 16548929
[TBL] [Abstract][Full Text] [Related]
18. The role of imagery in the maintenance and treatment of snake fear.
Hunt M; Bylsma L; Brock J; Fenton M; Goldberg A; Miller R; Tran T; Urgelles J
J Behav Ther Exp Psychiatry; 2006 Dec; 37(4):283-98. PubMed ID: 16473325
[TBL] [Abstract][Full Text] [Related]
19. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
20. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
